Sectra to Acquire AI Imaging Specialist Oxipit

Why It Matters

The deal accelerates Sectra’s AI‑enhanced radiology offering, promising higher throughput and lower costs for hospitals, while giving Oxipit broader regulatory support and market access.

Key Takeaways

• Sectra acquires AI imaging specialist Oxipit.
• ChestLink holds first CE Class 2B autonomous X‑ray certification.
• Deal financed with cash; milestones trigger additional payments.
• Oxipit team becomes Sectra’s dedicated AI development centre.
• AI integration aims to cut radiologist workload, boost productivity.

Pulse Analysis

The radiology market is undergoing a rapid digital transformation, with artificial intelligence emerging as a catalyst for efficiency and diagnostic accuracy. Sectra, a long‑standing provider of imaging IT solutions across Europe and beyond, has signaled its intent to deepen that transformation by acquiring Oxipit, a Swedish start‑up known for its autonomous AI algorithms. By bringing Oxipit’s technology in‑house, Sectra can embed machine‑learning capabilities directly into its existing workflow platforms, offering hospitals a seamless path from picture archiving to AI‑enhanced interpretation.

Oxipit’s flagship product, ChestLink, earned the first CE Class 2B certification for an autonomous chest‑X‑ray analysis tool, a milestone that validates both safety and performance under European regulations. The software automatically flags high‑confidence normal examinations, removing them from radiologists’ worklists and allowing clinicians to concentrate on abnormal or urgent cases. Continuous validation is built into the CE framework, ensuring the algorithm maintains clinical thresholds over time. With this certification, ChestLink can be distributed through Sectra’s Amplifier Marketplace, giving hospitals immediate access to a proven AI assistant without additional integration overhead.

The acquisition is being funded with cash up front, with additional payments tied to commercial and regulatory milestones, reflecting confidence in Oxipit’s growth trajectory. By integrating Oxipit’s R&D team as a dedicated AI centre within Sectra’s Imaging IT Solutions division, the combined entity can accelerate development of CT and musculoskeletal AI tools, extending the autonomous‑analysis portfolio beyond chest imaging. For healthcare providers, the move promises expanded capacity, reduced radiologist burnout, and measurable cost savings, while investors see a clearer path to monetising AI‑driven value‑added services in a competitive med‑tech landscape.

Deal Summary

Swedish medical imaging firm Sectra announced it will acquire AI imaging specialist Oxipit, developer of ChestLink, the first CE Class 2B certified autonomous AI for chest X‑ray analysis. The cash‑financed deal includes milestones tied to commercial and regulatory performance and is expected to close in the coming weeks. Financial terms were not disclosed.